Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Anne Beaven

Phase II Open Label Study of the Oral Vascular Endothelial Growth Factor-Receptor Inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients With Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Leukemia and Lymphoma

English

Durable Control of Mycosis Fungoides After Sepsis: “Coley’s Toxin?” Case Report and Review of the Literature

Case Reports in Hematology

2019

English

Related publications

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

English

Differential Effects of the Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 on Tumor Angiogenesis and Tumor Lymphangiogenesis

Molecular Cancer Therapeutics

Cancer Research

Oncology

2009

English

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Long-Term Follow-Up of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2019

English

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

Hematological Oncology

English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology

English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology

Oncology

2019

English

A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Anne Beaven

Phase II Open Label Study of the Oral Vascular Endothelial Growth Factor-Receptor Inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients With Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Durable Control of Mycosis Fungoides After Sepsis: “Coley’s Toxin?” Case Report and Review of the Literature

Related publications

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Differential Effects of the Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 on Tumor Angiogenesis and Tumor Lymphangiogenesis

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Long-Term Follow-Up of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma